Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04332653
Title NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NeoImmuneTech

lung non-small cell carcinoma

triple-receptor negative breast cancer

pancreatic cancer

lung small cell carcinoma

Advanced Solid Tumor

colorectal cancer


NT-I7 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.